Defective Breast Mesh, Acellular Dermal Matrix, and Bioabsorbable Scaffold Injury Attorneys in Louisiana: The Complete Guide for Women, Families, and Survivors

If you are reading this in Louisiana, there is a strong possibility that you or someone you love is navigating a medical crisis that feels as confusing as it is painful. Whether you underwent a post-mastectomy reconstruction at a major medical center in New Orleans, a cosmetic augmentation in Baton Rouge, or a breast lift in Shreveport, you trusted that the devices placed inside your body were vetted for safety. For many Louisiana women, that trust has been met with a series of complications—unexplained redness, chronic pain, late-onset swelling, or a terrifying diagnosis like BIA-ALCL or BIA-SCC.

We understand the emotional and physical toll this takes. Our firm has seen how a woman’s life can be upended when a surgical product marketed as a “support scaffold” or an “internal bra” becomes the source of a systemic health battle. This guide was created to serve as the definitive resource for Louisiana families. We will examine the federal regulatory failures that allowed these devices into Louisiana operating rooms, the specific brands involved, the science behind why they fail, and the unique legal framework in Louisiana that governs your right to seek justice. When you are ready to speak, our team at Attorney911—led by Ralph Manginello and the bilingual expertise of Lupe Peña—is here to listen.

Understanding the Devices: Mesh, ADM, and Scaffolds in Breast Surgery

In surgical suites across Louisiana, from the Ochsner Health system to the academic centers at LSU Health, plastic and reconstructive surgeons frequently use supplementary materials to support breast implants or native tissue. These products generally fall into three categories:

Acellular Dermal Matrix (ADM)

Often referred to as “biologic mesh,” ADM is tissue derived from human cadavers or animals (porcine or bovine). The manufacturer “strips” the cells that cause rejection, leaving behind a collagen scaffold. Brands like AlloDerm, Strattice, FlexHD, and AlloMax are marketed to help support the weight of an implant and provide a more natural aesthetic. However, the FDA has identified several of these—specifically FlexHD and AlloMax—as having significantly higher rates of infection and explantation.

Bioabsorbable Scaffolds

These are synthetic, dissolvable scaffolds designed to be absorbed by your body over 12 to 24 months. Products like GalaFLEX and Phasix are made of poly-4-hydroxybutyrate (P4HB). They are often marketed for “internal bra” procedures to reinforce a breast lift (mastopexy) or to support the lower part of a reconstruction. While they are meant to disappear, many Louisiana patients have reported that the scaffolds persist far longer than advertised, causing chronic inflammation, or degrade too quickly, leading to “bottoming out” and structural failure.

Synthetic Mesh

While less common for primary breast surgery, permanent synthetic meshes—often polypropylene—are sometimes used off-label. These permanent materials carry a high risk of erosion, where the mesh begins to migrate through the breast tissue or skin, a complication that almost always requires surgical intervention.

The Louisiana Medical Landscape and Your Reconstruction

Louisiana is home to a robust network of oncology and plastic surgery infrastructure. Patients often travel from Lafayette, Lake Charles, or the Northshore to seek specialized care at NCI-designated centers or high-volume hospital systems. We recognize that in our state, there are significant disparities in how healthcare is accessed, and unfortunately, these disparities can extend to informed consent.

Many Louisiana women were never told that the mesh or ADM used in their reconstruction was considered “off-label” for breast surgery. They weren’t told that the FDA has never actually determined the safety and effectiveness of surgical mesh for use in the breast. Whether you were treated at a regional referral hub or a solo aesthetic practice, you were entitled to know the risks. When manufacturers prioritize market share over patient safety, the women of Louisiana are the ones who pay the price in revision surgeries and lost health.

The Regulatory Root Cause: The 510(k) Clearance Shortcut

To understand why a device that causes such harm is in the market, we have to look at the FDA’s 510(k) clearance pathway. Most medical devices in the United States reach patients through this “substantial equivalence” framework under 21 CFR Part 807.

Under this rule, a manufacturer does not have to prove a device is safe or effective through human clinical trials. Instead, they only have to show that the new device is “substantially equivalent” to a “predicate device” already on the market. This has led to a phenomenon known as “predicate creep.” For example, the manufacturer of GalaFLEX cited a surgical suture as one of its predicates. Because a suture is safe, the logic goes, the mesh must be too.

The United States Supreme Court, in Medtronic v. Lohr, 518 U.S. 470 (1996), explicitly stated that 510(k) clearance is a comparative shortcut, not an evaluative finding of safety. Yet, manufacturers use this clearance to market these products to Louisiana surgeons as if they were fully vetted. At The Manginello Law Firm, PLLC, we focus on holding these companies accountable for using patients as “de facto” test subjects for devices that never underwent rigorous breast-specific testing.

Evidence of Concealment: Verified Whistleblower Records

The case against these manufacturers is strengthened by the testimony of insiders. Dr. Hooman Noorchashm, a cardiothoracic surgeon and former Medical Director at Becton Dickinson (BD), became a whistleblower after raising safety concerns. He has publicly alleged that BD, the maker of GalaFLEX and Phasix, withheld critical data from the FDA.

According to Dr. Noorchashm’s record, breast cancer recurrences in BD’s GalaFLEX clinical trials were not properly disclosed. He has also raised alarms regarding off-label promotion and the failure to provide detailed reports on patient harm in the Manufacturer and User Facility Device Experience (MAUDE) database. When a company’s own Medical Director sounds the alarm about patient safety and is subsequently terminated, it indicates a corporate culture that values revenue over the lives of women in Louisiana and across the country.

The Spectrum of Complications: What Louisiana Patients Experience

Complications from defective mesh and scaffolds are rarely “minor.” They often involve systemic immune responses or the need for multiple, invasive revision surgeries.

BIA-ALCL: Breast Implant-Associated Anaplastic Large Cell Lymphoma

This is a CD30-positive, ALK-negative T-cell lymphoma that develops in the scar tissue (capsule) around the implant. It is most strongly associated with textured-surface implants, such as the Allergan BIOCELL line which was recalled in July 2019. If you have been diagnosed with BIA-ALCL in Louisiana, your case aligns with active multi-district litigation (MDL 2921), where the first bellwether trials are approaching.

BIA-SCC: Breast Implant-Associated Squamous Cell Carcinoma

A more recently identified and aggressive cancer, BIA-SCC found in the implant capsule has prompted major FDA safety communications in 2022 and 2023. Unlike ALCL, it can be associated with both smooth and textured implants and often presents many years after the initial surgery.

Red Breast Syndrome (RBS) and Endotoxin Science

Many Louisiana patients experience persistent, sterile redness in the breast that looks like an infection but doesn’t respond to antibiotics. This is often Red Breast Syndrome, caused by endotoxins (bacterial fragments) that remain on acellular dermal matrix products even after sterilization. Studies have shown that brands like FlexHD and AlloMax carry higher risks of this inflammatory response.

Structural Failures and Scaffold Malposition

If your breast reconstruction has “bottomed out,” or if you can feel hard, sharp edges of a mesh years after it should have dissolved, you are likely dealing with a mechanical failure. GalaFLEX and Phasix have been reported to persist in the body well beyond their resorption window, acting as a permanent foreign body that triggers chronic pain and tissue erosion.

Louisiana Law and Your Rights: The Prescription Period

If you are a resident of Louisiana, your legal options are governed by a unique and notoriously strict framework. In Louisiana, the “statute of limitations” is called the Prescriptive Period. Under the Louisiana Civil Code, you generally have only one year from the date of the injury or the date you discovered the injury to file a lawsuit.

However, the “discovery rule” is vital here. Many women do not realize their mesh is the cause of their pain until they see a news report, receive a recall notice, or undergo a revision surgery where a new doctor identifies the device as the problem. Because the FDA only recently issued its strongest warnings in November 2023 regarding BD mesh products, many Louisiana women may still be within their legal window to file.

The Louisiana Products Liability Act (LPLA) provides the exclusive theories of recovery against manufacturers. We must prove that the product was unreasonably dangerous in construction, design, or because of an inadequate warning. This is why having an attorney admitted to federal practice in the Southern District of Texas (like Ralph Manginello) is beneficial; much of this litigation is handled in federal coordinated proceedings where deep command of the FDA’s 21 CFR regulations is required.

Why Choose The Manginello Law Firm for Your Louisiana Claim?

Navigating a defective medical device case requires more than just a general personal injury lawyer. It requires a team that understands pathology, regulatory law, and the tactics used by multi-billion dollar device companies.

27 Years of Continuous Practice

Ralph P. Manginello has been licensed since 1998 (Bar Card #24007597) and is admitted to the United States District Court for the Southern District of Texas. This federal admission is critical, as many Louisiana device cases take place in federal courts where multi-state litigation is coordinated. With an Avvo “Excellent” rating of 8.2 and a Martindale-Hubbell Preeminent rating, Ralph brings nearly three decades of high-stakes experience to your side.

Bilingual Representation with Lupe Peña

We recognize that Louisiana is a diverse state with a significant Spanish-speaking population, particularly in areas like Kenner, New Orleans, and Baton Rouge. Lupe Peña (Bar Card #24084332) of our firm is a third-generation Texan who is fully fluent in Spanish. She conducts full client consultations in Spanish without the need for interpreters, ensuring that every detail of your medical history and your suffering is understood directly by your legal team. Our ability to provide bilingual representation is a material asset for patients whose primary language is Spanish.

A Record of Institutional Accountability

Our firm doesn’t shy away from large-scale litigation. We are currently lead counsel in Bermudez v. Pi Kappa Phi, a high-profile $10 million lawsuit involving institutional liability and hazing. This experience in prosecuting complex, multi-defendant cases against large organizations—including national fraternities and university systems—mirrors the structural demands of suing global device manufacturers like Becton Dickinson or Allergan.

How to Determine Which Device Was Used

If you suspect your complications are linked to mesh or ADM, the first step is identifying the product. You generally won’t find this on your hospital discharge papers. You need to request your Operative Report and your Implant Log from the facility where your surgery took place.

Hospitals are required to keep “stickers” or logs containing the Unique Device Identifier (UDI), brand name, lot number, and expiration date for every implantable device. If you encounter resistance from a hospital in New Orleans, Baton Rouge, or elsewhere in Louisiana when requesting these records, contact us. As your attorneys, we can use legal discovery to secure the proof needed to link your injury to a specific defective device.

Frequently Asked Questions for Louisiana Patients

Is surgical mesh actually approved by the FDA for breast surgery?

No. The FDA confirmed in its November 9, 2023 letter that the safety and effectiveness of surgical mesh in breast surgery has not been determined. It is used “off-label,” meaning the manufacturer markets it for a use the FDA has not explicitly cleared.

What if my mesh was bioabsorbable and is now gone?

Even if a scaffold like GalaFLEX has partially resorbed, the damage it caused while in place—such as chronic inflammatory response, infection, or the loss of native tissue support—remains a basis for a claim. We look at the total trajectory of your injury.

What is the average settlement for a breast mesh case in Louisiana?

There is no “average” because these cases are still emerging. However, looking at comparable mass torts like pelvic mesh (billions in settlements) or hernia mesh (recent $1 billion resolution by BD), the potential for significant recovery is real. We seek damages for your medical bills, lost wages, permanent disfigurement, and the pain and suffering associated with losing your reconstruction.

Can Lupe Peña talk to me in Spanish about my case?

Sí. Lupe Peña realiza consultas completas en español. Ella entiende que para muchas familias en Louisiana, poder hablar directamente con su abogado en su propio idioma es esencial para la confianza y la claridad legal.

The Path Forward: Contact Attorney911 Today

You have navigated enough trauma. Between the original surgery, the subsequent complications, and the stress of medical bills, you deserve a legal team that takes the burden off your shoulders. The Manginello Law Firm, PLLC operates on a contingency fee basis, which means there is no upfront cost to you. We only get paid if we recover compensation for you.

We are ready to look at your medical records, listen to your story, and determine the best path forward under Louisiana law. Call us today at 1-888-ATTY-911 (1-888-288-9911) or contact us through our website. Whether you are in New Orleans, Baton Rouge, Shreveport, or a rural parish, we are committed to providing the aggressive, compassionate representation you need to hold these manufacturers accountable.

Past results do not guarantee future outcomes, but our 27 years of experience and our current role in major litigation like the Bermudez case prove that we have the resources to fight for the women of Louisiana. Let us help you find the justice you deserve.

Verifiable Legal Notice:
This content is provided by The Manginello Law Firm, PLLC (dba Attorney911). Ralph P. Manginello is the attorney responsible for this content. Principal office: 1177 West Loop South, Suite 1600, Houston, TX 77027. Admitted to the United States District Court for the Southern District of Texas. Lupe Peña is an associate attorney at the firm, fluent in Spanish. This information is for educational purposes and does not constitute legal advice or an attorney-client relationship until a written agreement is signed.

National Resources for Louisiana Patients:

• American Cancer Society (ACS): 1-800-227-2345 (24/7 Helpline, Spanish available).
• Susan G. Komen Breast Care Helpline: 1-877-465-6636.
• FORCE (Facing Our Risk of Cancer Empowered): facingourrisk.org (Specialized in BRCA and hereditary cancer patients).
• PROFILE Registry: ThePSF.org/PROFILE (For reporting BIA-ALCL cases).